Singapore markets close in 5 hours 6 minutes

Vaxart, Inc. (VXRT)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.6836-0.0226 (-3.20%)
At close: 04:00PM EDT
0.7000 +0.02 (+2.40%)
After hours: 07:47PM EDT

Vaxart, Inc.

170 Harbor Way
Suite 300
South San Francisco, CA 94080
United States
650 550 3500

Full-time employees109

Key executives

NameTitlePayExercisedYear born
Dr. Sean N. Tucker Ph.D.Senior VP & Chief Scientific Officer561.1kN/A1968
Dr. James F. Cummings M.D.Chief Medical Officer594.5kN/A1966
Mr. Steven LoPresident, CEO & DirectorN/AN/A1967
Mr. Phillip Eric LeeCFO, Principal Financial Officer & Principal Accounting OfficerN/AN/A1988
Dr. Raymond D. Stapleton Jr., Ph.D.Chief Technology OfficerN/AN/A1971
Mr. Edward B. BergSenior VP & General CounselN/AN/A1964
Ms. Shaily Jaini GargSenior Vice President of Clinical Development & Project ManagementN/AN/AN/A
Dr. Rajesh Kapoor Ph.D.Senior Vice President of QualityN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.

Corporate governance

Vaxart, Inc.’s ISS governance QualityScore as of 1 July 2024 is 9. The pillar scores are Audit: 9; Board: 8; Shareholder rights: 6; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.